Where Does VBI Vaccines Inc. (VBIV) Rank When It Comes To Price-To-Earnings Ratio?

0
11
NKE
NKE

VBI Vaccines Inc. (NASDAQ:VBIV) traded with a subtraction of -$0.04 to $0.72 on Thursday, a downside of -5.50 percent. An average of 1,342,658 shares of common stock have been traded in the last five days. There was a fall of -$0.1009 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,103,300 shares traded, while the 50-day average volume stands at 1,363,248.

VBIV stock has decreased by -19.78% in the last month. The company shares reached their 1-month lowest point of $0.7200 on 09/22/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.64 and a high of $3.49 in 52 weeks. It has reached a new high 1 time so far this year and lost -67.43% or -$1.6180 in price. In spite of this, the price is down -79.36% from the 52-week high.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Insider Transactions

295 days have passed since VBI Vaccines Inc. (VBIV) last reported insider trading activity. PERCEPTIVE ADVISORS LLC, who is 10% Owner, most recently acquired $2,707,463 shares at $3.31 per share on Dec 01.

Valuation Metrics

VBI Vaccines Inc. (VBIV) stock’s beta is 1.85. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 298.17, the price-to-book (PB) ratio at 1.86.

Financial Health

The quick ratio of VBI Vaccines Inc. for the three months ended March 30 was 2.20, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.20 and a total debt to equity ratio of 0.28 for the quarter ending March 30. Its gross profit as reported stood at -$10.14 million compared to revenue of $0.63 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, VBI Vaccines Inc.’s return on assets was -50.70%.

Earnings Surprise

For the three-month period that ended March 30, VBI Vaccines Inc. had $21.16 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$45.7 million in the quarter, while revenues of -$21.25 million were grew 61.75%. The analyst consensus anticipated VBI Vaccines Inc.’s latest quarter earnings to come in at -$0.08 per share, but it turned out to be -$0.08, a 0.00% surprise. For the quarter, EBITDA amounted to -$21.95 million. Shareholders own equity worth $258.26 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at VBI Vaccines Inc. (VBIV) price momentum. RSI 9-day as of the close on 21 September was 24.51%, suggesting the stock is oversold, with historical volatility in this time frame at 42.58%.

As of today, VBIV’s price is $0.7584 -12.26% or -$0.1009 from its 5-day moving average. VBIV is currently trading -25.69% lower than its 20-day SMA and -42.24% lower than its 100-day SMA. However, the stock’s current price level is -16.12% below the SMA50 and -67.33% below the SMA200.

The stochastic %K and %D were 3.75% and 6.30%, respectively, and the average true range (ATR) was 0.0597. With the 14-day stochastic at 0.91% and the average true range at 0.0671, the RSI (14) stands at 32.57%. The stock has reached -0.0417 on the 9-day MACD Oscillator while the 14-day reading was at -0.0716.

Analyst Ratings

The consensus rating for VBI Vaccines Inc. (VBIV) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VBIV, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 3 others rate it as a “buy”.

What is VBIV’s price target for the next 12 months?

Analysts predict a range of price targets between $5.00 and $7.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for VBI Vaccines Inc. (VBIV) stock is $6.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here